JCJean Chastre

Jean Chastre

*This is an algorithmically generated author record based on publicly available information.

Jean Chastre has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Charles-Edouard Luyt

    Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France

    3 shared publications
  • Alain Combes

    Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France

    2 shared publications
  • Jean-Yves Fagon

    Hôpital Européen Georges−Pompidou

    2 shared publications
  • Ivan Goldstein

    Réanimation Chirurgicale Pierre Viars, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France

    1 shared publication
  • Jean-Jacques Rouby

    Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care Medicine, Clinical Research Group (GRC) 29, DMU DREAM, La Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne University, Paris, France

    1 shared publication
  • Jean-Louis Trouillet

    Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Use of Quantitative Cultures and Reduced Duration of Antibiotic Regimens for Patients with Ventilator-Associated Pneumonia to Decrease Resistance in the Intensive Care Unit

    by Jean Chastre, Charles-Edouard Luyt, Alain Combes, Jean-Louis Trouillet

    Ventilator-associated pneumonia is responsible for approximately half of the infections acquired in the intensive care unit and represents one of the


  • Novel and Innovative Strategies to Treat Ventilator-Associated Pneumonia: Optimizing the Duration of Therapy and Nebulizing Antimicrobial Agents

    by Ivan Goldstein, Jean Chastre, Jean-Jacques Rouby

    Ventilator-associated pneumonia (VAP) is responsible for approximately half of the infections acquired in the intensive care unit (ICU) and represents one of the principal reasons for prescribing antibiotics in this setting. Because unnecessary prolongation of antimicrobial therapy and insufficient dosing of antibiotics at the site of infection in patients with true bacterial infection may lead to the selection of multidrug-resistant microorganisms without improving clinical outcome, efforts to reduce the duration of therapy and optimize pulmonary penetration of antimicrobial agents are warranted. An 8-day regimen can probably be standard for patients with VAP. Possible exceptions to this recommendation include immunosuppressed patients, those whose initial antimicrobial treatment was not appropriate for the causative microorganism(s), and patients whose infection was caused by very difficult-to-treat microorganisms and had no improvement in clinical signs of infection. Nebulizing concentration-dependent antibiotics such as aminoglycosides during mechanical ventilation can markedly increase tissue penetration in foci of pneumonia as compared with intravenous administration. The superiority in terms of pulmonary penetration and antibacterial efficacy of this route of administration was demonstrated in a model of ventilated piglets with and without bronchopneumonia.


  • Ventilator-Associated Pneumonia

    by Jean Chastre

    Figure 1 Ventilator-associated pneumonia (VAP), which is usually defined as an infection occurring more than 48 hours after hospital admission in a patient requiring mechanical ventilation, is an entity that should be viewed as a subcategory of health care-associated pneumonia (HCAP). HCAP includes any patient who was hospitalized in an acute care hospital for 2 or more days within 90 days of the infection; resided in a nursing home or long-term care facility; received recent antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic. VAP is the most frequent intensive care unit (ICU)-acquired infection among patients receiving mechanical ventilation. In contrast to infections of other frequently involved organs (e.g., urinary tract and skin), for which mortality is low, the mortality rate for VAP ranges from 20 to 50% and can reach 70% in some specific settings or when lung infection is caused by high-risk pathogens or when initial antibiotic therapy is inappropriate. This issue of Seminars in Respiratory and Critical Care Medicine includes contributions from world-renowned experts in the field of VAP who have provided state-of-the-art information on important aspects of the clinical management of this dreadful disease. In the first article, Isakow and Kollef describe an evidence-based approach of modifiable risk factors for preventing VAP. They reviewed all the literature concerning modifiable risk factors and respiratory care for the prevention of VAP and presented a very detailed and comprehensive discussion of each potential prophylactic measure. Some very simple, safe, inexpensive, and logical measures, including avoiding nasal insertion of endotracheal and gastric tubes; keeping patients in the semirecumbent position, especially in the case of enteral nutrition; and removal of tubing condensate may have a tremendous impact on the frequency of VAP in mechanically ventilated patients. However, because respiratory tract colonization of ICU patients is generally very complex, corresponding to a mix of self-colonization and cross-transmission, only a multifaceted and multidisciplinary program can be effective. In the second article, Bonten and Krueger describe the rationale of selective decontamination of the digestive tract (SDD) as an infection control strategy designed to prevent VAP. After more than 20 years, SDD is still a controversial issue in intensive care medicine. Nevertheless, the debate is now enriched with results from large clinical trials in well-defined patient populations. The extremely beneficial outcomes of some of these recent studies should be confirmed, preferably in multicenter trials, because liberal use of SDD (or any antimicrobial prophylactic strategy) may lead to escalating antimicrobial resistance. Because antibiotic resistance has become a worldwide concern, the debate as to whether infections caused by resistant bacteria are associated with higher mortality has been ongoing. As rightly underscored by Combes and colleagues, resistant strains do not appear to be more virulent than those susceptible to the usual antibiotics. Thus differences in outcome may principally relate to patient characteristics before or at the time of infection onset, and to high rates of inappropriate empirical antimicrobial treatment prescribed for antibiotic-resistant infections. Two articles in this issue provide up-to-date information regarding how to improve the diagnosis of bacterial infection in mechanically ventilated patients. In the first one, Dr. Gibot discusses why the measurement of the soluble form of the triggering receptor expressed on myeloid cells (sTREM)-1 in bronchoalveolar lavage fluid may be useful as a diagnostic tool. Of course, like every biomarker, sTREM-1 will never substitute for a broad microbiological examination, and its interpretation must be correlated with a careful clinical evaluation. Nevertheless, in the difficult context of sepsis, sTREM-1 may accelerate and improve the diagnostic process, especially in patients having received prior antibiotics before evaluation. In the second one, Dr. Fagon reviews the potential advantages of a diagnostic strategy based on fiberoptic bronchoscopy and quantitative cultures in ventilated patients with signs suggestive of pneumonia. Although the true impact of this decision tree on patient outcome remains controversial, being able to withhold antimicrobial treatment from some patients without infection may constitute a distinct advantage in the long term by minimizing the emergence of resistant microorganisms in the ICU and redirecting the search for another (the true) infection site. Five articles, by Drs. Niederman, Kiem and Schentag, Eggimann and Revelly, Goldstein and colleagues, and Lam and Wunderink, are devoted to the treatment of the disease. In the first one, Dr. Niederman underscores that antimicrobial therapy of patients with VAP should follow a two-stage process. The first stage involves administering broad-spectrum antibiotics to avoid inappropriate treatment in patients with true bacterial pneumonia. The second stage focuses on achieving this objective without overusing and abusing antibiotics, combining several different steps, such as stopping therapy in patients with a low probability of the disease, streamlining treatment once the etiologic agent is known, and shortening duration of therapy to 7 or 8 days, as dictated by the patient's clinical response to therapy and information about the bacteriology of the infection. Antibiotic therapy is generally considered to be appropriate or concordant when in vitro susceptibilities of the administered antibiotics cover the isolated pathogens. However, we need to go a step further and improve the way we give antibiotics to patients with VAP, as reviewed by Drs. Kiem and Schentag. Scrupulous attention must be given to...


  • Conference Summary: Ventilator-Associated Pneumonia

    by Jean Chastre

    Ventilator-associated pneumonia (VAP), which is usually defined as an infection occurring greater than 48 hours after hospital admission in a patient requiring mechanical ventilation, is an entity that should be viewed as a subcategory of health-care-associated pneumonia, which includes any patient who was hospitalized in an acute care hospital for 2 or more days within 90 days of the infection; resided in a nursing home or long-term care facility; received recent antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic. VAP is the most frequent intensive-care-unit (ICU)-acquired infection among patients receiving mechanical ventilation. In contrast to infections of other frequently involved organs (eg, urinary tract and skin), for which mortality is low, the mortality rate for VAP ranges from 20% to 50% and can reach 70% in some specific settings or when lung infection is caused by high-risk pathogens and/or when initial antibiotic therapy is inappropriate. Although the attributable mortality rate for VAP is still debated, it has been shown that these infections prolong both the duration of ventilation and the duration of ICU stay. These prolonged hospitalizations underscore the considerable financial burden imposed by the development of VAP. The causes of VAP are many and may vary by hospital, patient population, and type of ICU, emphasizing the need for timely, local surveillance data. In many cases infection is caused by multiple-drug-resistant pathogens. Risk factors for such resistant microorganisms are the duration of mechanical ventilation, prior antibiotic treatment, and contact with the health care system. Preventive measures should be guided with regard to a full understanding of pathogenesis and epidemiology. Because respiratory-tract colonization of ICU patients is generally very complex, corresponding to a mix of self-colonization and cross-transmission, only a multifaceted and multidisciplinary program can be effective. Antimicrobial therapy of patients with VAP should follow a 2-stage process. The first stage involves administering broad-spectrum antibiotics to avoid inappropriate treatment in patients with true bacterial pneumonia. The second stage focuses on trying to achieve this objective without over-using and abusing antibiotics, combining a number of different steps, such as stopping therapy in patients with a low probability of the disease, streamlining treatment once the etiologic agent is known, switching to monotherapy after days 3-5, and shortening duration of therapy to 7-8 days, as dictated by the patient's clinical response to therapy and information about the bacteriology of the infection.


  • The Invasive (Quantitative) Diagnosis of Ventilator-Associated Pneumonia

    by Jean Chastre, Alain Combes, Charles-Edouard Luyt

    Although appropriate antibiotics may improve survival in patients with bacterial pneumonia, use of empirical broad-spectrum antibiotics in patients without infection is potentially harmful, facilitating colonization and superinfection with multiresistant microorganisms. Invasive diagnostic methods, including bronchoalveolar lavage and/or protected-specimen bronchial brushing, could improve identification of patients with true bacterial pneumonia and facilitate decisions whether or not to treat, and thus clinical outcome. Bronchoalveolar lavage and/or protected-specimen bronchial brushing permit collecting distal pulmonary secretions with minimal or no upper-airway contamination, either through a fiberoptic bronchoscope or blindly using an endobronchial catheter that is wedged in the tracheobronchial tree. Due to the inevitable oropharyngeal bacterial contamination that occurs in the collection of all respiratory secretion samples, quantitative culture techniques are always needed to differentiate oropharyngeal contaminants present at low concentration from higher-concentration infecting organisms. Because even a few doses of a new antimicrobial agent can negate results of microbiologic cultures, pulmonary secretions in patients suspected of having developed pneumonia should always be obtained before new antibiotics are administered. Bronchoalveolar lavage may also provide useful clues for the diagnosis of other forms of respiratory failure, such as pulmonary hemorrhage or other types of infections, especially in immunocompromised patients.


  • Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia

    by Charles-Edouard Luyt, Jean Chastre, Jean-Yves Fagon, the VAP Trial Group

    To evaluate the potential ability of an algorithm based on the clinical pulmonary infection score (CPIS) to identify and treat patients with bacterial ventilator-associated pneumonia (VAP) compared to a strategy based on quantitative cultures of bronchoscopic specimens. Retrospective cohort study. Thirty-one critical care units across France. Two hundred and one patients clinically suspected of having VAP who had been included in the “invasive strategy” group of the French multicenter randomized trial and for whose quantitative cultures bronchoscopic specimens were obtained. CPIS was determined retrospectively, based on data that had been collected for the initial study. None. The clinical pulmonary infection score was determined on days 1 and 3, and compared in patients identified as having developed VAP or not, as defined by bronchoscopic specimen culture results. On day 3 138 of the 201 patients (69%) had a CPIS of more than 6 that would have required prolonged antimicrobial therapy based on the algorithm. In contrast, based on bronchoscopy, only 88 (44%) patients were considered to have VAP (kappa coefficient for concordance between the two strategies, 0.33). While the sensitivity of CPIS more than 6 on day 3 for identifying VAP was 89%, its specificity was only 47%, leading to potentially unnecessary treatment of 60 (53%) of the 113 patients without VAP as diagnosed by bronchoscopy. A strategy based on the CPIS to decide which patients with suspected VAP should receive prolonged administration of antibiotics would appear to over-prescribe these agents, as compared to a strategy based on bronchoscopy.


  • Infections due toAcinetobacter Baumanniiin the ICU

    by Jean Chastre

    Acinetobacter species are widespread environmental, nonfermentative, aerobic, gram-negative coccobacilli. Most infections due to this organism are opportunistic in nature and occur in patients who spend extended time in the intensive care unit (ICU) due to severe underlying disease, and who need prolonged therapy with mechanical ventilation and antimicrobial agents. Because the only factor amenable to prevention in this setting is antimicrobial therapy, avoidance of unnecessary antibiotics should be a high priority in management of such patients. Nosocomial spread of A. baumannii in the ICU setting has often been attributed to ventilatory equipment and to colonized nursing and respiratory personnel via hand transmission. In fact, the epidemiology of nosocomial respiratory colonization and/or infection with A. baumannii is now commonly much more complex due to the coexistence of epidemic cases with unrelated sporadic cases caused by different strains. This underscores the necessity to use molecular typing to improve the detection of microepidemics amenable to early control. Crude mortality rates of 30 to 75% have been reported for nosocomial infection due to Acinetobacter species, with the highest rates reported in ventilator-dependent patients. As with many other opportunistic gram-negative bacilli, increasing antibiotic resistance has hindered the therapeutic management of nosocomial infection due to Acinetobacter species. A. baumannii are now frequently resistant to most available antibacterial drugs, with some centers reporting up to 80% of strains resistant to all aminoglycosides. Even resistance to imipenem, which was for several years the most effective drug in treating Acinetobacter nosocomial infections, has now been described in several reports. Unfortunately, the unique propensity of Acinetobacter species to develop resistance to multiple antimicrobial agents reinforces concerns about the imminence of a post-antimicrobial era where no effective antibiotics will be available to treat this type of infection.


  • Top Cited Papers

    Ventilator-associated Pneumonia

    by Jean Chastre, Jean-Yves Fagon

    Ventilator-associated pneumonia (VAP) continues to complicate the course of 8 to 28% of patients receiving mechanical ventilation (MV). In contrast to infections of more frequently involved organs (e.g., urinary tract and skin), for which mortality is low, ranging from 1 to 4%, the mortality rate for VAP ranges from 24 to 50% and can reach 76% in some specific settings or when lung infection is caused by high-risk pathogens. The predominant organisms responsible for infection are Staphylococcus aureus, Pseudomonas aeruginosa, and Enterobacteriaceae, but etiologic agents widely differ according to the population of patients in an intensive care unit, duration of hospital stay, and prior antimicrobial therapy. Because appropriate antimicrobial treatment of patients with VAP significantly improves outcome, more rapid identification of infected patients and accurate selection of antimicrobial agents represent important clinical goals. Our personal bias is that using bronchoscopic techniques to obtain protected brush and bronchoalveolar lavage specimens from the affected area in the lung permits physicians to devise a therapeutic strategy that is superior to one based only on clinical evaluation. When fiberoptic bronchoscopy is not available to physicians treating patients clinically suspected of having VAP, we recommend using either a simplified nonbronchoscopic diagnostic procedure or following a strategy in which decisions regarding antibiotic therapy are based on a clinical score constructed from seven variables. Selection of the initial antimicrobial therapy should be based on predominant flora responsible for VAP at each institution, clinical setting, information provided by direct examination of pulmonary secretions, and intrinsic antibacterial activities of antimicrobial agents and their pharmacokinetic characteristics. Further trials will be needed to clarify the optimal duration of treatment and the circumstances in which monotherapy can be safely used.